• LAST PRICE
    0.9764
  • TODAY'S CHANGE (%)
    Trending Down-0.0136 (-1.3688%)
  • Bid / Lots
    0.9607/ 5
  • Ask / Lots
    0.9920/ 1
  • Open / Previous Close
    0.9800 / 0.9899
  • Day Range
    Low 0.9600
    High 1.0000
  • 52 Week Range
    Low 0.6640
    High 2.2000
  • Volume
    5,816
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 0.9899
TimeVolumeCING
10:04 ET14000.98
10:18 ET2000.9602
10:27 ET5000.976
10:36 ET2000.96
11:36 ET1000.9889
11:41 ET14960.960419
12:08 ET5430.97635
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesCING
Cingulate Inc
11.2M
-0.6x
---
United StatesNEXI
Neximmune Inc
11.0M
-0.2x
---
United StatesCYCC
Cyclacel Pharmaceuticals Inc
11.4M
-0.5x
---
United StatesCNTX
Context Therapeutics Inc
10.9M
-1.2x
---
United StatesBUDZ
Weed Inc
10.9M
-9.3x
---
United StatesBRTX
BioRestorative Therapies Inc
11.0M
-0.2x
---
As of 2023-01-31

Company Information

Cingulate Inc. is a clinical stage biopharmaceutical company. The Company is focused on the development, manufacturing and commercialization of pharmaceutical products that utilize precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles that improves the lives of patients suffering from a multitude of commonly diagnosed conditions. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The Company is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). Its CTx-1301 and CTx-1302 drug candidates both contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form. Its CTx-1301 and CTx-1302 that are being developed for the treatment of ADHD, in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+).

Contact Information

Headquarters
1901 W. 47Th PlaceKANSAS CITY, KS, United States 66205
Phone
913-942-2300
Fax
302-636-5454

Executives

Chairman of the Board, Chief Executive Officer, Co-Founder
Shane Schaffer
Co-Founder, Executive Vice President, Chief Science Officer
Raul Silva
Co-Founder, Executive Vice President, General Counsel, Secretary
Craig Gilgallon
Co-Founder, Executive Vice President, Chief Medical Officer
Matthew Brams
Chief Financial Officer, Executive Vice President
Louis Van Horn

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$11.2M
Revenue (TTM)
$0.00
Shares Outstanding
11.3M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-1.51
Book Value
$1.84
P/E Ratio
-0.6x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.